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1. Introduction
Metabolic syndrome (MetS) is characterized by increased
visceral fat and insulin resistance, both of which are
associatedwith an increased risk of developing type 2 diabetes
(T2D) and cardiovascular disease (CV) [1]. Despite the
increased prevalence of MetS worldwide [2], the underlying
pathophysiology in the development of CV disease is still
incompletely understood. Recent studies have clearly estab-
lished the association of MetS with markers of systemic
inflammation, including C-reactive protein (CRP), tumor
necrosis factor (TNF)-a and interleukin (IL)-6, all of which
may play a role in the development of obesity-related insulin
resistance and other co-morbidities including diabetes,
hypertension and CV diseases [3].
Atherosclerosis is characterized by a long clinically silent
phase before overt disease manifestation and frequently
precedes the diagnosis of MetS [4] or T2D [5]. Identifying
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Aims: Metabolic syndrome (MetS) is associated with increased cardiovascular risk. We
hypothesize that early vascular changes are already present at the time of diagnosis of
MetS. The relationship of different measures of early vascular impairment with body fat
distribution and the natural progression ofMetSwas examined in newly diagnosed subjects
non-pharmacologically treated.
Methods: 246 consecutively enrolled subjects were categorized according to the presence of
MetS and type 2 diabetes (T2D). Intra-renal Doppler flow was used to ascertain resistive (RI)
and pulsatility (PI) indices as markers of vascular resistance. Carotid intima-media thick-
ness (IMT), cutis-rectis (CR) and rectis-aorta (RA) thicknesses were measured by ultrasono-
graphy; RA/CR ratio was used as measure of body fat distribution. Pro-inflammatory
cytokines, C-reactive protein, oxidative markers insulin and adiponectin blood concentra-
tions were also measured.
Results: Baseline characteristics demonstrated increasing trends in biochemical, inflam-
matory, and oxidative parameters from MetS, MetS+, to MetS+/T2D ( p < 0.001). After
adjusting for age, the same increasing trends across the groups were observed in both
sexes in IMT ( p < 0.001), RI ( p < 0.001) and PI ( p < 0.001). IMT correlated with RI (r = 0.25;
p < 0.001), PI (r = 0.26; p < 0.001), and RA/CR ratio (r = 0.43; p < 0.001).
Conclusions: Carotid IMT and intra-renal resistances are elevated at an early stage in MetS
and are associated with a dysregulated production of fat-derived hormones and cytokines.
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clinicalmarkers of early vascular change in the initial stages of
MetS and T2D may improve the understanding of the
mechanisms involved in the development of atherosclerosis
[6]. High-resolution B-mode pulsed-wave Doppler ultrasound,
which measures carotid intima-media thickness (IMT) and
pulsatility (PI) and resistive (RI) indices calculated from the
blood flow velocity in intra-renal interlobar arteries is
promising [7,8]. Elevated RI and PI suggest increased intra-
renal resistances, which are correlated with carotid IMT [9]
and are increased in patients with T2D, hypertension or
chronic renal failure [8–10]. This may also be associated with
endothelial dysfunction [11] as subjects with hypertension
[12], diabetes [13], or obesity [14] often exhibit a higher carotid
IMT than control subjects. An increased carotid IMT is a well-
known marker of subclinical atherosclerosis, and strongly
predicts the occurrence of myocardial infarction and stroke
[7,15]. Furthermore, increased intra-renal RI and PI values also
reflect end-organ damage, characterized by glomerular and
arteriolar sclerosis [16]. Increased intra-renal resistances
might indicate, at least at an early stage, a functional and
reversible modification consequent to intra-renal vasocon-
striction due to endothelial dysfunction [11]. This activity
might be antecedent to the appearance of structural changes
consequently causing arterial atherosclerosis and glomerular
ischemia [17].
We hypothesize that earlymarkers of vascular impairment
and subclinical atherosclerosis are already present in subjects
at time of first diagnosis ofMetS, and thatmeasures of body fat
distribution are associated with such different stages. We
speculate that there is a continuum in obese patients without
MetS to those with MetS and diabetes. Studies investigating
the relationships between carotid IMT, intra-renal resistances,
body fat distribution and markers of endothelial function and
inflammation at the time of diagnosis of MetS are lacking. In
the present study, we selected newly diagnosed and untreated
subjects with MetS, with or without T2D, and measured the
intra-renal RI and PI, carotid IMT and serum blood concentra-
tions of inflammatory and oxidative stress markers to
investigate any possible relationships with early atherosclero-
sis.
2. Patients and methods
2.1. Subjects
Three hundred forty-one consecutive overweight or obese
subjects (age range: 30–60 years; BMI range: 25–39.9 kg/m2)
were recruited among the Obesity and Related Diseases
Outpatient Department seen at the Department of Internal
Medicine, Cardiovascular and Kidney Diseases of the Uni-
versity of Palermo between January 2006 and June 2008.
Patients were referred to the clinic by their physicians for
management of obesity or for a new diagnosis of hyperten-
sion, T2D, or MetS. Patients had no other systemic or end-
organ disease on the basis of clinical history and physical
examination, routine blood tests and electrocardiogram, nor
were they on pharmacological treatment for obesity-related
disorders, including anti-hypertensive, blood-glucose low-
ering and antiplatelet drugs. Nineteen subjects refused to
participate in the study for personal reasons, 39 cases were
excluded due to technical difficulties in performing the echo-
Doppler renal hemodynamicmeasurements, and 37 cases due
to logistic and administrative difficulties. The remaining 246
subjects with complete data were classified into three groups
on the basis of their clinical and laboratory data: no MetS
(MetS); MetS present (MetS+); and MetS with T2D (MetS+/
T2D). Metabolic syndrome was defined according to both the
NCEP-ATP-III [18] and additionally determined using the
International Diabetes Foundation criteria [19]; T2D was
defined according to the American Diabetes Association
criteria [20]. The study protocol was approved by the Ethics
Committee of our Institution. All study participants were
informed about aims andmethods and gave voluntarywritten
consent.
2.2. Blood sampling
A blood venous sample was obtained after an overnight fast to
assess biochemical data including high-sensitivity C-reactive
protein (Diagnostic Biochem, London, Ontario, Canada; CRP),
insulin (radioimmunoassay; Insik-5, DiaSorin, Saluggia, Italy;
mU/ml), IL-6 (Endogen Human IL-6 ELISA; Pierce Biotech.
Rockford, IL, USA; pg/ml), TNF-a (Amersham Biosciences
ELISA kit; Little Chalfont, UK; pg/ml), 8-iso-prostaglandin F2a
(Assay Design Inc ELISA, Ann Arbor, MI, USA; 8-iso-PGF2a, pg/
ml) and adiponectin (Human Adiponectin ELISA Kit; B-Bridge
International CA, USA; mg/ml). Low-density lipoprotein (LDL)
cholesterol concentration was calculated according to the
Friedewald formula [21]. Glomerular filtration rate (GFR) was
calculated according to MDRD equations [22]. The home-
ostasismodel assessment of insulin resistance (HOMA-IR) was
calculated according to Matthews et al. [23].
2.3. Body composition and fat distribution
Fat mass (FM, % body weight) was estimated as previously
described [24] by means of bioelectrical impedance analysis
(BIA-103, RJL, Detroit, MI, USA/Akern, Florence, Italy). Anthro-
pometric measurements were obtained at the umbilicus
(waist circumference) and at the most prominent buttock
level (hip circumference); their ratio (waist-to-hip ratio, WHR)
was considered as a measure of body fat distribution.
Abdominal visceral and subcutaneous adipose sizes were
also measured by means of high-resolution B-mode ultra-
sound (Sonoline G50; Siemens; Germany) [25]. Transverse
scans were obtained 5 cm above the umbilicus along the
xipho-umbilical line. A 10-MHz linear probe was used to
measure the distance between the cutis and the conjunction
of rectus muscles at the linea alba (cutis-rectis thickness; CR),
as ameasure of the subcutaneous fat. A 3.5-MHz convex probe
measured the distance between the linea alba and the anterior
wall of the abdominal aorta (rectis-aorta thickness, RA), as a
measure of visceral abdominal fat. The RA to CR ratio (RA/CR)
was also considered an indirect measure of body fat distribu-
tion. A single physician (SB) was responsible for performing
the ultrasonographic body fat thickness examinations. Our
laboratory intra-observer coefficient of variation for CR is 1.2%
and that for RA is 3.9% including subjects with a BMI range of
18–45 kg/m2.
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2.4. Carotid and renal ultrasound analysis
Images of the right and left extracranial carotid artery walls
were obtained in several projections by a high-resolution
ultrasonographic 10-MHz linear array probe; end-diastolic
intima-media thickness of the far wall of both common
carotid arteries wasmeasured 10 mm caudal to the bulb, from
the anterior, lateral and posterior approaches using two-
dimensional longitudinal sections of the vessel and the
distance from the first echogenic line to the second echogenic
line; themean of both sidesmeasurementswas considered for
calculations [26]. A single physician (SB) was responsible for
performing the carotid and renal ultrasonographic examina-
tions who was not blinded to the study hypothesis. Renal
Doppler flow was obtained (3.5 MHz probe) of the interlobar
arteries by placing the Doppler sample volume at three
different positions (superior, mid and inferior) in each of both
kidneys, guided by color flow mapping [27]. The mean of both
kidneys resistive indices [RI; (peak systolic velocity  end-
diastolic velocity)/peak systolic velocity] and pulsatility index
[PI; (peak systolic velocity  end-diastolic velocity)/mean
velocity] were obtained. The measured values were assessed
by a different physician (SV).
2.5. Statistical analysis
All data are presented asmeans  standard error ofmeans. All
variables with skewed distribution were log-transformed
Table 1 – Characteristics of the study population – using NCEP-ATP-III criteria [18].
MetS
(N = 123)
MetS+
(N = 87)
MetS+/T2D
(N = 36)
Pa
ANOVA MetS vs.
MetS+
MetS vs.
MetS+/T2D
MetS+ vs.
MetS+/T2D
Males/females 53/70 45/42 16/20
Age (years) 45  1 47  1 53  1 <0.001 NS <0.001 0.011
Smokers (%) 14.6 14.9 13.8
Systolic (mmHg) 130  2 141  2 142  2 <0.001 <0.001 0.001 NS
Diastolic (mmHg) 83  1 90  1 86  2 <0.001 <0.001 NS NS
Hypertension (%) 54.5 67.8 63.9
Biochemical parameters
Creatinine (mg/dl) 0.91  0.02 0.95  0.02 0.91  0.03 NS
GFR (ml/min 1.73 m2) 109  2 112  3 109  5 NS
Cholesterol (mg/dl) 203  4 203  5 216  8 NS
HDL cholesterol (mg/dl) 52.7  1.3 39.9  0.9 43.4  1.5 <0.001 <0.001 <0.001 NS
LDL cholesterol (mg/dl) 120  3 133  4 140  8 NS
Triglycerides (mg/dl) 105  5 150,4  8,5 154  12 <0.001 <0.001 <0.001 NS
Uric acid (mg/dl) 5.0  0.2 5.5  0.2 5.7  0.3 0.023 0.029 NS NS
Glucose (mg/dl) 91.8  0.9 98.0  1.2 148.9  7.2 <0.001 NS <0.001 <0.001
Glycated hemoglobin (%) 5.4  0.1 5.5  0.1 7.8  0.5 <0.001 NS < 0.001 < 0.001
Insulin (mU/ml) 28.4  0.9 35.5  1.5 36.7  1.6 <0.001 <0.001 0.001 NS
HOMA-I 6.5  0.2 8.5  0.4 12.1  0.9 <0.001 <0.001 <0.001 <0.001
Ultrasonographic parameters
RA (mm) 64  3 89  4 110  12 <0.001 <0.001 <0.001 NS
CR (mm) 38  1 32  2 23  3 <0.001 0.016 <0.001 0.009
RA/CR 1.7  0.1 2.8  0.3 4.8  0.8 <0.001 <0.001 <0.001 <0.001
Anthropometric measurements
Body weight (kg) 82.4  1.5 90.2  2.1 89.6  3.4 0.008 0.010 NS NS
BMI (kg/m2) 30.5  0.4 33.0  0.6 34.3  0.9 <0.001 0.004 <0.001 NS
FM (%) 34.4  0.9 32.4  0.9 32.6  2.0 NS
Waist circumference (cm) 99  1 112  2 108  3 <0.001 <0.001 <0.001 NS
Hip circumference (cm) 110  1 117  2 112  3 0.007 0.020 NS NS
WHR 0.91  0.01 0.97  0.01 0.96  0.02 <0.001 0.002 0.001 NS
Cytokines + oxidative stress markers
Adiponectin (mg/ml) 6.8  0.2 5.8  0.2 5.3  0.3 <0.001 <0.001 <0.001 NS
CRP (mg/l) 1.61  0.04 1.89  0.06 2.26  0.11 <0.011 <0.001 <0.001 0.002
IL-6 (pg/ml) 73.9  2.4 88.9  2.6 110.3  3.9 <0.001 <0.001 <0.001 <0.001
TNF-a (pg/ml) 3.1  0.1 3.3  0.1 3.7  0.1 <0.001 0.002 <0.001 <0.001
8-iso-PGF2a (pg/ml) 162.8  5.0 202.2  6.4 248.8  13.2 <0.001 <0.001 <0.001 0.001
All values expressed as mean  SEM, or count (%).
BMI, body mass index; CR, cutis-rectis thickness; CRP, C-reactive protein; FM, fat mass; GFR, glomerular filtration rate; HOMA-I, homeostasis
model assessment-insulin resistance; IL-6, interleukine-6; 8-iso-PGF2a, 8-iso-prostaglandin F2a; MetS, metabolic syndrome; RA, rectis-aorta
thickness; T2D, type 2 diabetes; TNF-a, tumor necrosis factor-a; WHR, waist-to-hip ratio.
a p values calculated using analysis of variance (ANOVA); when ANOVA was significant (p < 0.05), pairwise comparisons among groups were
tested using the Bonferroni’s t-test.
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when appropriate. Data are presented by sex and in
aggregate where indicated. A one-way ANOVA was used to
compare the group effect. When the ANOVA was statistically
significant ( p < 0.05) pairwise comparisons among groups
were tested and a Bonferroni adjustment was performed.
Linear regression analysis was performed to assess the
primary outcomes of IMT, intra-renal RI and PI, after
adjusting for age and sex, on the three groups (MetS,
MetS+, MetS+/T2D). Exploratory analyses were performed to
assess the predictors of IMT, PI and RI according to the
number of MetS categories but also to assess the strength
and independency of associations between variables using
multiple regression analysis (stepwise forward selection).
Correlations are expressed by the Pearson’s correlation
coefficient. A two-tailed p < 0.05 was considered significant.
All analyses were performed using SYSTAT (Windows
version 11.0; San Jose, CA, USA).
3. Results
Baseline characteristics are reported in Table 1. There were
123 patients in the MetS group, 87 patients in the MetS+
group, and 36 patients in the MetS+/T2D group applying the
ATP-III criteria for MetS. When the IDF diagnostic criteria of
MetSwere considered, fewer subjectswere classified asMetS
(n = 90) while an increased number of MetS+ subjects (n = 120)
was included (Table 2). Physical, clinical, biochemical data, RI,
PI, and IMT did not change differently across the three groups
of studied subjects according to classification criteria of the
IDF or the ATP-III.
Age increased from the MetS to MetS+ to MetS+/T2D
group. Patients with MetS+ or MetS+/T2D had a higher BMI
than MetS patients. All measures of body fat distribution
demonstrated that body fat significantly increased towards a
more visceral pattern of distribution from the MetS to the
Table 2 – Characteristics of the study population – using IDF criteria [19].
MetS (N = 90) MetS+ (N = 120) MetS+/T2D (N = 36) Pa
Males/females 42/48 56/64 16/20
Age (years) 45  1 46  1 53  1 <0.001
Smokers (%) 13.3 12.1 13.8
Systolic (mmHg) 130  2 142  2 142  2 <0.001
Diastolic (mmHg) 82  1 89  1 86  2 <0.001
Hypertension (%) 47.8 53.2 63.9
Biochemical parameters
Creatinine (mg/dl) 0.91  0.02 0.94  0.02 0.91  0.03 NS
GFR (ml/min 1.73 m2) 105  5 103  4 109  5 NS
Cholesterol (mg/dl) 204  4 202  4 216  8 NS
HDL cholesterol (mg/dl) 54.3  1.4 41  0.8 43.4  1.5 <0.001
LDL cholesterol (mg/dl) 131  4 131  4 140  8 NS
Triglycerides (mg/dl) 96  4 143  6 154  12 <0.001
Uric acid (mg/dl) 5.1  0.1 5.6  0.1 5.7  0.3 0.040
Glucose (mg/dl) 90.4  1.0 97.1  1.0 148.9  7.2 0.001
Glycated hemoglobin (%) 5.3  0.1 5.4  0.1 7.8  0.5 <0.001
Insulin (mU/ml) 28.3  1.1 33.7  1.2 36.7  1.6 <0.001
HOMA-I 6.4  0.3 8.1  0.3 12.1  0.9 <0.001
Ultrasonographic parameters
RA (mm) 70  2 80  2 110  12 <0.001
CR (mm) 34  1 32  1 23  3 <0.001
RA/CR 2.4  0.1 3.1  0.1 4.8  0.8 <0.001
Anthropometric measurements
Body weight (kg) 81.8  1.6 88.6  1.8 89.6  3.4 0.027
BMI (kg/m2) 30.3  0.4 32.5  0.6 34.3  0.9 <0.001
FM (%) 33.8  1.1 33.4  0.8 32.6  2.0 NS
Waist circumference (cm) 99  1 106  1 108  3 <0.001
Hip circumference (cm) 108  1 112  1 112  3 0.004
WHR 0.92  0.01 0.95  0.01 0.96  0.02 0.003
Cytokines + oxidative stress markers
Adiponectin (mg/ml) 6.9  0.2 6.0  0.1 5.3  0.3 <0.001
CRP (mg/l) 1.61  0.04 1.83  0.05 2.26  0.11 <0.001
IL-6 (pg/ml) 75.0  2.9 83.9  2.3 110.3  3.9 <0.001
TNF-a (pg/ml) 3.1  0.04 3.2  0.1 3.7  0.1 <0.001
8-iso-PGF2a (pg/ml) 161.5  5.4 192.4  5.8 248.8  13.2 <0.001
All values expressed as Mean  SEM.
BMI, body mass index; CR, cutis-rectis thickness; CRP, C-reactive protein; FM, fat mass; GFR, glomerular filtration rate; HOMA-I, homeostasis
model assessment-insulin resistance; IL-6, interleukine-6; 8-iso-PGF2a, 8-iso-prostaglandin F2a; MetS, metabolic syndrome; RA, rectis-aorta
thickness; T2D, type 2 diabetes; TNF-a, tumor necrosis factor-a; WHR, waist-to-hip ratio.
a p values calculated using analysis of variance (ANOVA).
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MetS+ groups. The ultrasonographic data demonstrated that
across the three groups, from the MetS to the MetS+/T2D,
concomitant to a progressive increase of visceral adipose
tissue (RA), there was a reduction of subcutaneous adipose
tissue (CR). Othermeasurements demonstrated similar trends
between each of the groups (MetS vs. MetS+ vs. MetS+/T2D).
Univariate trendswere similar by sex (Table 3) andnodifferent
in females ormales; trendswere replicated in themultivariate
linear regression analysis after adjusting for age. There were
significant differences in IMT, RI and PI between the MetS
group and MetS+ groups, and from the MetS+ group to the
MetS+/T2D groups, using either criteria.
Table 4 presents data in relation to the number of
components of ATP-III-MetS in our exploratory analysis.
IMT increased significantly across as the number of MetS
components increased (0–5 components) and as well as when
they were grouped in three class groups (0–1, 2–3, 4–5
components). No significant change was observed with regard
Table 3 – Carotid intima-media thickness, intra-renal hemodynamic data, of the study participants divided by sex and
according to the presence (+) or absence (S) of metabolic syndrome (NCEP-ATP-III [18] and IDF [19] criteria) associated or
less to diabetes.
Univariate analysis Age-adjusted linear regression analysis
MetS MetS+ MetS+/T2D ANOVA, p MetS MetS+ MetS+/T2D Pa
ATP-III
IMT (mm)
M 0.653  0.021 0.735  0.021 0.815  0.026 <0.001 0.646  0.010 0.717  0.011 0.861  0.019 <0.001
F 0.616  0.017 0.725  0.025 0.862  0.048 <0.001 0.610  0.010 0.735  0.012 0.819  0.014 <0.001
RI
M 0.655  0.005 0.660  0.006 0.710  0.017 <0.001 0.644  0.002 0.652  0.002 0.681  0.003 <0.001
F 0.670  0.004 0.699  0.008 0.707  0.017 <0.001 0.658  0.002 0.678  0.002 0.698  0.002 <0.001
PI
M 1.150  0.018 1.174  0.025 1.374  0.094 <0.001 1.155  0.007 1.195  0.007 1.294  0.012 <0.001
F 1.190  0.014 1.310  0.035 1.315  0.071 0.003 1.199  0.008 1.282  0.009 1.349  0.010 <0.001
IDF
IMT (mm)
M 0.659  0.025 0.714  0.020 0.815  0.026 0.002 0.679  0.014 0.683  0.011 0.756  0.018 0.005
F 0.624  0.022 0.682  0.020 0.862  0.048 <0.001 0.690  0.016 0.712  0.012 0.761  0.014 0.027
RI
M 0.653  0.006 0.661  0.005 0.710  0.017 <0.001 0.653  0.003 0.653  0.002 0.670  0.004 0.005
F 0.669  0.005 0.689  0.006 0.707  0.017 0.012 0.679  0.004 0.684  0.003 0.695  0.003 0.027
PI
M 1.141  0.020 1.176  0.021 1.374  0.094 <0.001 1.159  0.011 1.163  0.008 1.219  0.014 0.005
F 1.189  0.019 1.269  0.025 1.315  0.071 0.034 1.227  0.011 1.242  0.008 1.274  0.009 0.0271
All values expressed as mean  SEM.
F, females; IMT, intima-media thickness; M, males; MetS, metabolic syndrome; PI, intra-renal pulsatility index; RI, intra-renal resistance index;
T2D, type 2 diabetes.
a Adjusted p value for age.
Table 4 – Carotid intima-media thickness, intra-renal hemodynamic data of the study participants divided according to
increasing number of determinants of metabolic syndrome (NCEP-ATP-III criteria) [18].
0 1 2 3 4 5 ANOVA, p
Subjects (N) 25 55 68 59 30 9
IMT (mm) 0.568  0.030 0.647  0.018 0.688  0.020a 0.776  0.024b,d,e 0.733  0.027c 0.800  0.057c <0.001
RI 0.669  0.005 0.664  0.005 0.675  0.007 0.688  0.007 0.676  0.008 0.678  0.025 NS
PI 1.171  0.018 1.174  0.019 1.239  0.029 1.247  0.028 1.233  0.034 1.302  0.142 NS
0–1 2–3 4–5 ANOVA, p
Subjects (N) 80 126 40
IMT (mm) 0.622  0.016 0.729  0.016f 0.747  0.024 <0.001
RI 0.666  0.004 0.681  0.005 0.676  0.008 NS
PI 1.173  0.014 1.243  0.020g 1.247  0.040 <0.05
All values expressed as mean  SEM. Bonferroni’s t-test: ap < 0.02 vs. 0; bp < 0.001 vs. 0; cp < 0.005 vs. 0; dp < 0.001 vs. 1; ep < 0.05 vs. 2; fp < 0.001
vs. 0–1; gp < 0.05 vs. 0–1.
IMT, intima-media thickness; MetS, metabolic syndrome; PI, intra-renal pulsatility index; RI, intra-renal resistance index; T2D, type 2 diabetes.
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to the RI, while PI increased significantly onlywhen grouped in
three class of number of components ofMetS. Fig. 1 represents
the relationships between the primary outcomes of IMT, PI
and RI with ultrasonographic anthropometric measurements.
IMT was significantly associated with RI (r = 0.25; p < 0.001)
and PI (r = 0.26; p < 0.001). Table 5 reports the independent
predictors of IMT, RI and PI.
4. Discussion
The results of this study suggest that MetS, especially when
associated with T2D, is characterized by higher values of
carotid IMT, an indicator of subclinical atherosclerosis, but
also by higher intra-renal resistances as assessed by RI and PI.
Body fat distribution, hormonal, inflammatory and oxidative
markers reported in the three studied groups are also in
agreement with the hypothesis of a natural progression of the
MetS that is associated with a progressive vascular impair-
ment. This study’s novelty is that we are not aware of other
studies investigating these relationships particularly in obese
patients managed non-pharmacologically. Therefore, the
implications of this study provide further insight into the
natural history, progression and pathophysiology of insulin
resistance and the MetS.
It has been described that subjects with T2D have the same
risk of developing myocardial infarction [28] or stroke [29] as
non-diabetic patients who already had cardiovascular events.
Previously, an adverse cardiovascular risk profile may ante-
cede the diagnosis of diabetes [30]. Subsequent data obtained
from the Nurses’ Health Study cohort [5] confirmed impaired
cardiovascular risk before the clinical diagnosis of diabetes.
Our results demonstrating increased carotid IMT and intra-
renal resistances in subjects with newly diagnosed MetS or
MetS with T2D are in accordance with our hypothesis that
the atherosclerotic process is initiated before the clinical
Fig. 1 – Correlations between log-transformed main outcomes of the study and echographic measures of body fat
compartments. IMT: carotid intima-media thickness; RI: renal resistance index; PI: renal pulsatility index; CR: cutis-rectis
thickness; RA: rectis-aorta thickness.
d i a b e t e s r e s e a r c h and c l i n i c a l p r a c t i c e 8 6 ( 2 0 0 9 ) 1 7 7 – 1 8 5182
Author's personal copy
appearance of diabetes. Furthermore, contrary to carotid IMT
results, the association between intra-renal resistances and the
number of components of MetS (Table 4) was less significant
with respect to grouping subjects according to the presence of
MetS and T2D. The latter finding is in agreement with the
hypothesis that MetS per se and not its single components are
associated with increased risk. Although all the individual
components may be individual risk factors impacting renal
resistance indices, they also may interact with one another in
differentways leading to different effects.However,we caution
the validity of these additional analyses as not only were we
limited in study power among the six groups (0–5 components),
but we would currently be unable to ascertain the effect of the
interaction between these components. We hypothesize that
with a higher number of subjects, this modelling may have
demonstrated stronger associations.
Our study proved that intra-renal RI and PI were correlated
with carotid IMT. Studies in subjects with kidney diseases
showed an association between renal resistance indices and
local renal impairment, demonstrating their ability to predict
kidney diseases. Few studies investigated the association
between intra-renal hemodynamic indices and carotid IMT
exclusively in subjects with hypertension [9,27,31], with
chronic kidney diseases [32] or kidney transplanted [33]. A
major limitation of these studies, though, was their rather
small sample sizes [9,27,32]. However, the association
between carotid IMT and intra-renal indices of vascular
resistance in hypertensive patients without known organic
kidney damage suggests that these indices may have a more
complex pathophysiologic significance likely reflecting sys-
temic vascular disease. To the best of our knowledge, our
results confirm the association between intra-renal hemody-
namic indices and carotid IMT in nonpharmacologically
treated subjects with MetS without renal disease, suggesting
that increased intra-renal resistances reflect a systemic
vascular impairment. Since an increased carotid IMT is known
to be associated with impaired endothelial function [34], our
results may also lend credence to the hypothesis that
endothelial dysfunction may have vasoconstrictor effects
[11] and therefore induce elevated intra-renal RI and PI. To the
best of our knowledge, there is no data examining the
discriminatory differences between intra-renal PI and RI
compared to carotid IMT.Whether one technique is preferable
or more predictive than the other on incident vascular disease
or endothelial dysfunction requires further investigation.
Interestingly, the blood concentrations of 8-iso-PGF2a, a
molecule considered a marker of oxidative stress [35],
correlated significantly with IMT, RI and PI.
Total adiposity (FM%) was not significantly different
between the three groups and it was independent and
negatively correlated with IMT and intra-renal PI (data
reported in Appendix). This apparently contradictory result
is explained at least in part by the negative correlation
between these variables and CR thickness. In fact, subcuta-
neous fat is better represented in women than in men and
accounts for the higher total fat mass commonly observed in
women. Despite the association betweenwaist circumference
and visceral fat, it cannot discriminate subcutaneous from
visceral fat at the individual level [25]. Therefore, the elevated
subcutaneous fat sizes in women may explain their lower
cardiovascular risk compared to men, despite the higher BMI
and waist circumference observed in females. These con-
siderations may have at least two possible implications:
methods to intervene reducing excess body weight likely need
to have sex-specific targets, possibly on the basis of a more
accurate body fat measurement [36]; and secondly, body
circumferences are probably inaccurate measures of body fat
distribution in pathophysiology studies that consider limited
numbers of subjects of both sexes. Our study’s echographic CR
and RA thicknesses, as direct measurements of body fat
compartments are safe, cost-effective and relatively easy to
perform method with good reproducibility, compared to
highly accurate but costly and impractical methods such as
dual x-ray absorptiometry, nuclear magnetic resonance or
computer tomography; furthermore, our results are in agree-
ment with studies that demonstrate that ultrasonography can
estimate not only visceral obesity but also risks of cardiovas-
cular andmetabolic diseases [37,38]. The RA/CR discriminated
better thanWHR subjectswithMetS from thosewithMetS and
T2D and it was positively correlated with the carotid IMT and
the intra-renal RI and PI. The results emphasize the role of the
balance between visceral and subcutaneous adipose tissue
compartments in the pathogenesis of atherosclerosis.
We acknowledge that increased visceral fat co-exists with
insulin resistance and that inflammatory cytokines are over-
produced in visceral fat together with other markers not
measured in this study [39]. Not surprisingly, our correlations
confirm that low circulating levels of adiponectin are a
characteristic of the MetS [40], and that increased visceral
fat is associated with a shift in the normal balance of the
adipokines resulting in a pro-inflammatory state; however,
subcutaneous fat is thought to have a protective role fromboth
the metabolic and the cardiovascular point of view, likely
because it might be a preferential site of adiponectin
production [41]. We cannot exclude that subcutaneous fat
has not only a neutral role in terms of metabolic and
cardiovascular risk but that itmay actively antagonize visceral
fat and that the echographic derived ratio RA/CR is an
appropriate measurement when the influences of body fat
distribution is investigated.
Our study has inherent limitations. The limited number of
subjects was not homogeneous as far as age and sex
distribution, but we were able to adjust for this in our
multivariable analysis. Despite the prevalence of hyperten-
sionwas similar in theMetS groups, it was slightly lower in the
group without MetS, this difference was due to the particular
procedure of enrolment of subjects in the study design.
However, we feel that such a little difference does not fully
explain differences observed in the main outcomes. A study
with a higher number of enrolled subjects is probably needed
to confirm these preliminary results. The data collected by
ultrasonography were measured by an individual clinician
that was not blinded to the study hypothesis. This inherently
involves diagnostic suspicion bias, and measurement bias.
Alternatively, we should have collected multiple measure-
ments by different observers to minimize such bias. However,
to what extent this may have affected our results is unknown.
In addition, ascertaining independent predictors of our out-
come variables including determinants of the number of MetS
components require further investigation.
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We demonstrated that using the IDF criteria for MetS, the
prevalence in each category differed from that observed using
the ATP-III criteria. This is an expected result because of the
more inclusive nature of the IDF criteria. Although there is
debate as to which definition of MetS is more accurate [2], this
was outside the scope of the current study. More importantly,
though, the outcome data and their trends were no different
using these different classification criteria. Other studies have
consistently used ATP-III definitions allowing better compar-
ison with our own results [42,43].
The study design was prospective in nature, allowing the
investigation of untreated subjects with newly diagnosed
MetS or MetS/T2D, thus excluding any pharmacologic
influence on hemodynamic intra-renal measurements.
Furthermore, ultrasound measurements were performed
by the same operator thus excluding inter-observer varia-
bility. We have made inherent assumptions regarding the
underlying pathophysiology of theMetS, including that there
is a natural progression between each stage of disease.
However, this has been confirmed in other studies [44], and
indeed our data provide further evidence to this fact. In our
community, primary care physicians often refer patients
with obesity or at high risk for cardiometabolic abnormal-
ities to our clinic, and although does not eliminate referral
bias completely, as in a population-based cohort, it mini-
mizes it to a large degree. Hence, our results have good
external validity.
In summary, we have demonstrated that newly diagnosed
MetS is characterized by increased carotid IMT and intra-renal
resistances, implicating that this clinical condition recognizes
specific pathogenic mechanisms involving body fat distribu-
tion, insulin resistance and inflammation.
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